Promising single-agent efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib supports the notion that BCR signaling is essential in the pathogenesis of ABC DLBCL and MCL [8, 9]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.